February 12, 2019
1 min watch
Save

VIDEO: Phase 2 data show IOP reduction for 1 year with iDose

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO — At the Glaucoma 360: New Horizons Forum, L. Jay Katz, MD, chief medical officer at Glaukos, discusses phase 2 data for the company’s iDose device, which releases a continuous dose of travoprost.